Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07545837 | Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | recruiting | N/A | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06788002 | LDRT and Chemoimmunotherapy in NPC With Liver Metastasis(Light) | recruiting | Phase 2 | 26 | Hunan Cancer HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686575 | Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma | recruiting | — | 20 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05522881 | The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | recruiting | — | 410 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04892303 | Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer | recruiting | Phase 1 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04151082 | High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors | recruiting | Phase 1 / Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04290663 | Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up(INTERMEDIATE) | recruiting | Phase 3 | 368 | Centre Francois BaclesseOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06592599 | Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) | recruiting | Phase 2 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06961084 | Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer | recruiting | Phase 2 | 62 | Thomas HopeOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05172921 | Environmental Factors and Thyroid Cancer | recruiting | — | 500 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06682442 | Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma | recruiting | N/A | 66 | University of California, San FranciscoOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07600580 | The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response | recruiting | Phase 4 | 48 | University Hospital DubravaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02747888 | Hereditary Risk Factors for Thyroid Cancer | recruiting | N/A | 250 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07634978 | Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients | recruiting | N/A | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06287034 | The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF) | recruiting | — | 102 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06821243 | Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention | recruiting | — | 40 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07618078 | Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07068542 | Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | recruiting | N/A | 94 | Zhejiang Provincial People's HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT03039439 | Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors | recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04589624 | An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy | recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05800574 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | recruiting | Phase 2 | 22 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07325539 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC(LIGHT) | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07376837 | Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study(PTC-RFA) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07497607 | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma(REDUCE-30) | recruiting | Phase 2 | 31 | Sara MedekOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05420948 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | recruiting | Phase 2 | 30 | University of ChicagoOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06747390 | Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery(856397) | recruiting | Phase 1 | 30 | Ryan CareyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581821 | Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 33 | Ming-Yuan ChenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04436965 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | recruiting | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05340491 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05941741 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | recruiting | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06197776 | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC | recruiting | — | 50 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06323239 | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | recruiting | Phase 1 / Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06984861 | A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | recruiting | Phase 2 | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06997068 | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population | recruiting | Phase 2 | 25 | Mayo ClinicOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04425265 | Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma | recruiting | N/A | 500 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 8, 2026source: clinicaltrials